The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group is a new Leadership Group representing a merger of investigators from the Pediatric AIDS Clinical Trials Group (PACTG) and the Perinatal Scientific Working Group of the HIV Prevention Trials Network (HPTN/HIVNET). The group will be headed by the group chair, Brooks Jackson, MD, MBA (Johns Hopkins). Social &Scientific Systems, Inc. (SSS), will be the Coordinating and Operations Center (CORE). The Statistical Data Management Center (SDMC) for the IMPAACT group will be SDAC/FSTRF headed by Terence Fenton, Ed.D (Harvard). The Central Laboratory Network for the group will be headed by Susan Fiscus, PhD (U North Carolina).The mission of the IMPAACT group, which is worldwide in scope, will be to significantly decrease the mortality and morbidity associated with HIV disease in pregnant women, infants, children, and adolescents by: 1) Developing and evaluating safe and cost effective approaches for the interruption of mother-to infant Transmission; 2) Evaluating treatments for HIV-infected children, adolescents, and pregnant women, including treatment and prevention of co-infections and co-morbidities; 3) Evaluating vaccines for the prevention of HIV sexual transmission among adolescents. IMPAACT has an ambitious scientific agenda which proposes to carry forward 28 PACTG, four HPTN, and one ATN treatment and prevention trials (transition protocols) and develop 26 new protocols. In the first year, we estimate that IMPAACT will enroll and/or follow approximately 9,434 women, children, and adolescents in developing countries into 23 protocols (eight new and 15 transition protocols) and 1,479 subjects in the United States into 19 protocols (four new and 15 transition protocols). These protocols will be in four of the six RFA-designated high-priority areas (PMTCT, translational research/drug development, optimization of clinical management including co-morbidities, and vaccines). Due to the requirements of the RFA, HIV vaccine trials for prevention of breastfeeding transmission are described and budgeted in the PMTCT section, therapeutic vaccine trials in the translational research section, and HIV prophylactic vaccine trials for adolescents and preadolescents to prevent sexual transmission in the Vaccine section.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-KS-A (J1))
Program Officer
Miller, Judith A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Mitchell, Charles D; Chernoff, Miriam C; Seage 3rd, George R et al. (2015) Predictors of resolution and persistence of renal laboratory abnormalities in pediatric HIV infection. Pediatr Nephrol 30:153-65
Ciaranello, Andrea; Lu, Zhigang; Ayaya, Samuel et al. (2014) Incidence of World Health Organization stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) East Africa regional anal Pediatr Infect Dis J 33:623-9
Ciaranello, Andrea L; Leroy, Valeriane; Rusibamayila, Asinath et al. (2014) Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival. AIDS 28 Suppl 3:S287-99
Watts, D Heather; Stek, Alice; Best, Brookie M et al. (2014) Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr 67:375-81
Tobin, Nicole H; Aldrovandi, Grace M (2014) Are infants unique in their ability to be "functionally cured" of HIV-1? Curr HIV/AIDS Rep 11:1-10
Lindsey, Jane C; Hughes, Michael D; Violari, Avy et al. (2014) Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J 33:846-54
Yin, Dwight E; Warshaw, Meredith G; Miller, William C et al. (2014) Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. Pediatrics 134:e1104-16
Clarke, Diana F; Acosta, Edward P; Rizk, Matthew L et al. (2014) Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr 67:310-5
Desmonde, Sophie; Essanin, Jean-Bosco; Aka, Addi E et al. (2014) Morbidity and health care resource utilization in HIV-infected children after antiretroviral therapy initiation in Côte d'Ivoire, 2004-2009. J Acquir Immune Defic Syndr 65:e95-103
Fowler, Mary Glenn; Coovadia, Hoosen; Herron, Casey M et al. (2014) Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr 65:366-74

Showing the most recent 10 out of 41 publications